Guggenheim cuts Travere Therapeutics target price to $78 from $89
TVTX•Guggenheim cut its target price for Travere Therapeutics to $78 from $89.
Related News
Nucor Corporation: KeyBanc raises target price to $301 from $286
NUE•
Markets fret blue wave will drown data centres
SPY•
Driven Brands Holdings Inc.: Canaccord Genuity cuts target price to $12 from $18
DRVN•
Asia hopes Democrats can curb Trump's Iran war and tariffs: Russell
SPY•
Thomson Reuters target price raised by CIBC to $139 from $124
TRI•